List of Field Safety Notices from 29 September to 3 October 2025.
Similar Posts
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.
Class 4 Medicines Defect Notification: Relonchem Ltd, Various Products, EL(25)A/44
Relonchem Ltd has informed the MHRA that duplicate GTIN numbers have been assigned to certain Losartan potassium/Hydrochlorothiazide coated tablets in error and a duplicate EAN number has been assigned to certain Risperidone tablets in error.
Guidance: GLP-1 medicines for weight loss and diabetes: what you need to know
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
MHRA Safety Roundup: July 2025
Summary of the latest safety advice for medicines and medical device users
Decision: Parallel import licences granted in 2026
Parallel import licences granted in 2026.
Device specific vigilance guidance: Artificial Heart Valves
Guidance for manufacturers of artificial heart valves. It outlines specific scenarios that should be considered when determining if an incident is reportable.